Drug intelligence / Profile preview

Paratus multiple target cardiometabolism program

Development stage: Preclinical
Lead developer: Paratus Sciences

Overview

Paratus Sciences is developing a preclinical-stage therapeutic program targeting multiple undisclosed pathways for the treatment of cardiometabolic diseases. The company's discovery platform is centered on the unique evolutionary adaptations of bats, which exhibit remarkable metabolic regulation and inflammatory control. This specific program is currently in the early stages of target identification or lead optimization, and details regarding the specific molecular targets, mechanism of action, or therapeutic modality (such as small molecules or biologics) have not yet been disclosed by the developer.

Other names: Unnamed Cardiometabolism Multiple TargetsParatus-Multiple targets (undisclosed)-Cardiometabolism (unspecified)

Beyond the preview

Go deeper on Paratus multiple target cardiometabolism program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paratus multiple target cardiometabolism program.

Explore the full profile